Eli Lilly and Company $LLY Shares Sold by Teewinot Capital Advisers L.L.C.

Key Points

• Teewinot Capital Advisers L.L.C. has reduced its stake in Eli Lilly by 25.8%, now holding 72,820 shares, making it the firm's 6th largest investment at 6.1% of its portfolio.
• Eli Lilly reported strong quarterly earnings of $6.31 per share, exceeding estimates, with a revenue of $15.56 billion, up 37.6% year-over-year.
• The company declared a quarterly dividend of $1.50 per share, representing an annualized dividend yield of 0.8% and a payout ratio of 39.22%.

Teewinot Capital Advisers L.L.C. decreased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 25.8% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 72,820 shares of the company's stock after selling 25,287 shares during the quarter. Eli Lilly and Company comprises about 6.1% of Teewinot Capital Advisers L.L.C.'s portfolio, making the stock its 6th biggest holding. Teewinot Capital Advisers L.L.C.'s holdings in Eli Lilly and Company were worth $60,143,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. WestEnd Advisors LLC increased its position in shares of Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after acquiring an additional 21 shares during the period. Wealth Preservation Advisors LLC acquired a new position in Eli Lilly and Company during the 1st quarter worth $27,000. Citizens National Bank Trust Department increased its holdings in Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after purchasing an additional 27 shares during the period. Financial Gravity Asset Management Inc. purchased a new stake in Eli Lilly and Company during the 1st quarter worth about $40,000. Finally, TD Capital Management LLC raised its position in Eli Lilly and Company by 129.2% in the 1st quarter. TD Capital Management LLC now owns 55 shares of the company's stock valued at $46,000 after purchasing an additional 31 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of LLY stock traded up $11.35 during midday trading on Tuesday, hitting $749.99. The company had a trading volume of 2,983,536 shares, compared to its average volume of 4,436,129. The stock has a market cap of $709.84 billion, a price-to-earnings ratio of 49.02, a PEG ratio of 1.03 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The company's 50 day simple moving average is $743.02 and its 200 day simple moving average is $779.63. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $942.35.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period in the previous year, the firm earned $3.92 EPS. The business's revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be given a $1.50 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. Eli Lilly and Company's dividend payout ratio (DPR) is currently 39.22%.

Insider Transactions at Eli Lilly and Company

In related news, Director J Erik Fyrwald purchased 1,565 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the acquisition, the director owned 74,578 shares in the company, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Daniel Skovronsky acquired 1,000 shares of the company's stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the purchase, the executive vice president directly owned 137,660 shares of the company's stock, valued at approximately $87,331,504. This trade represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 4,514 shares of company stock valued at $2,894,841 in the last quarter. Insiders own 0.14% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently commented on LLY shares. Erste Group Bank downgraded shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. Cantor Fitzgerald lowered their price objective on Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating for the company in a research report on Wednesday, August 13th. Deutsche Bank Aktiengesellschaft dropped their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a report on Monday, August 11th. Daiwa America cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 17th. Finally, Wall Street Zen raised Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 30th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $950.17.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.